Xeris Biopharma Holdings Inc [XERS] stock prices are up 2.28% to $7.17 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The XERS shares have gain 10.14% over the last week, with a monthly amount drifted -5.53%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Xeris Biopharma Holdings Inc [NASDAQ: XERS] stock has seen the most recent analyst activity on December 09, 2025, when Barclays initiated its Overweight rating and assigned the stock a price target of $9. On November 11, 2024, downgrade downgraded it’s rating to Neutral but maintained its price target of $3 on the stock. Oppenheimer started tracking the stock assigning an Outperform rating and suggested a price target of $5 on March 28, 2024. Craig Hallum initiated its recommendation with a Buy and recommended $4.50 as its price target on August 28, 2023. Jefferies started tracking with a Buy rating for this stock on October 21, 2022, and assigned it a price target of $4. In a note dated April 28, 2022, Craig Hallum initiated a Buy rating and provided a target price of $6.50 on this stock.
The stock price of Xeris Biopharma Holdings Inc [XERS] has been fluctuating between $3.14 and $10.08 over the past year. Currently, Wall Street analysts expect the stock to reach $13.5 within the next 12 months. Xeris Biopharma Holdings Inc [NASDAQ: XERS] shares were valued at $7.17 at the most recent close of the market. An investor can expect a potential return of 88.28% based on the average XERS price forecast.
Analyzing the XERS fundamentals
The Xeris Biopharma Holdings Inc [NASDAQ:XERS] reported sales of 266.14M for trailing twelve months, representing a surge of 37.06%. Gross Profit Margin for this corporation currently stands at 0.81% with Operating Profit Margin at -0.04%, Pretax Profit Margin comes in at -0.14%, and Net Profit Margin reading is -0.13%. To continue investigating profitability, this company’s Return on Assets is posted at -0.1, Equity is 1.14 and Total Capital is -0.04. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-13.32.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.05 points at the first support level, and at 6.92 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.25, and for the 2nd resistance point, it is at 7.32.
Ratios To Look Out For
It’s worth pointing out that Xeris Biopharma Holdings Inc [NASDAQ:XERS]’s Current Ratio is 1.93. As well, the Quick Ratio is 1.35, while the Cash Ratio is 0.62. Considering the valuation of this stock, the price to sales ratio is 4.47.
Transactions by insiders
Recent insider trading involved BARBARA-JEAN A BORMANN-KENNEDY, Director, that happened on Dec 12 ’25 when 15000.0 shares were purchased. Hecht Beth completed a deal on Dec 01 ’25 to sell 16667.0 shares. Meanwhile, Shannon John Patrick Jr sold 23242.0 shares on Nov 13 ’25.
